| Bioactivity | Carmegliptin is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a substrate of P-glycoprotein that synergizes with Verapamil (HY-14275). Carmegliptin improves insulin sensitivity and reduces hepatic glucose production in hyperglycemic mice. Carmegliptin is promising for research of type 2 diabetes, hypertension and cardiovascular disease[1][2]. |
| CAS | 813452-18-5 |
| Formula | C20H28FN3O3 |
| Molar Mass | 377.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mattei P, et al. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1109-13. [2]. Kuhlmann O, et al. Interaction potential of Carmegliptin with P-glycoprotein (Pgp) transporter in healthy volunteers. J Drug Assess. 2014 Mar 3;3(1):28-37. |
Carmegliptin
CAS: 813452-18-5 F: C20H28FN3O3 W: 377.45
Carmegliptin is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a subst
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.